Bicycle Therapeutics plc (BCYC) — Stock Score Summary

Bicycle Therapeutics plc (BCYC) has a MoatMap StockRank of 12/100 based on Quality (31/100), Value (44/100), and Momentum (20/100) factor scores. The current signal is STRONG SELL. Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics. While its bicyclic peptide platform is scientifically interesting, it is pre-revenue, highly speculative, and currently lacks the high ROIC, pricing power, and established reinvestment runway required by the Terry Smith lens.

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company pioneering a novel class of medicines called Bicycles®, which are synthetic short peptides with unique therapeutic properties. The company leverages its proprietary Bicycle® platform to develop highly selective and potent small-molecule-like biologics for oncology and other therapeutic areas. This innovative drug modality aims to address difficult-to-drug targets and improve patient outcomes.

Key Financial Metrics

Price$4.17
Market Cap$326M
P/E (Forward)-2.00
Price/Book0.54
Return on Equity-33.8%
Return on Invested Capital-33.1%
Debt/Equity2.77
Gross Margin-244.5%
Operating Margin-7382.4%
Revenue Growth-91.1%
Free Cash Flow$-110M

Bicycle Therapeutics plc operates in the Biotechnology industry, part of the Healthcare sector (United Kingdom).

Frequently Asked Questions

What is Bicycle Therapeutics plc’s (BCYC) StockRank?
MoatMap’s StockRank for Bicycle Therapeutics plc (BCYC) is 12/100, with a Strong Sell signal. It is a composite of Quality (31), Value (44), and Momentum (20) factor ranks across MoatMap’s 19,000+ stock universe.
Does Bicycle Therapeutics plc have an economic moat?
Bicycle Therapeutics plc (BCYC) has a Quality factor score of 31/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Bicycle Therapeutics plc a buy, hold, or sell?
MoatMap’s current signal for Bicycle Therapeutics plc (BCYC) is Strong Sell, based on a StockRank of 12/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Bicycle Therapeutics plc in?
Bicycle Therapeutics plc (BCYC) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).
Browse all ranked stocksBCYC deep dive reportAI ChampionsHow we score stocksSense-check another stock